Abstract
Stroke strikes often suddenly, causes long-term disability and death, and is a huge economical burden for the society, not to mention the human tragedy for the patient and the family. At least 15% of stroke survivors will have a second stroke during the next five years, quarter of which prove out to be fatal within four weeks [1]. Secondary prevention of ischemic stroke (IS) targets at reducing stroke recurrence by means of 1) detection and modification of risk factors, 2) antithrombotic or anticoagulant treatment, and 3) surgical interventions for selected patient subgroups. In this review we will discuss these issues in detail and also offer our personal suggestions for treatment choices. Detecting and treating the modifiable risk factors is the major challenge of secondary prevention of IS.
Keywords: stroke, prevention, cerebrovascular disease, risk factors, antithrombotic agents, brain infarct, endarterectomy
Current Drug Targets
Title: Secondary Prevention of Ischemic Stroke
Volume: 5 Issue: 5
Author(s): Kirsi Rantanen and Turgut Tatlisumak
Affiliation:
Keywords: stroke, prevention, cerebrovascular disease, risk factors, antithrombotic agents, brain infarct, endarterectomy
Abstract: Stroke strikes often suddenly, causes long-term disability and death, and is a huge economical burden for the society, not to mention the human tragedy for the patient and the family. At least 15% of stroke survivors will have a second stroke during the next five years, quarter of which prove out to be fatal within four weeks [1]. Secondary prevention of ischemic stroke (IS) targets at reducing stroke recurrence by means of 1) detection and modification of risk factors, 2) antithrombotic or anticoagulant treatment, and 3) surgical interventions for selected patient subgroups. In this review we will discuss these issues in detail and also offer our personal suggestions for treatment choices. Detecting and treating the modifiable risk factors is the major challenge of secondary prevention of IS.
Export Options
About this article
Cite this article as:
Rantanen Kirsi and Tatlisumak Turgut, Secondary Prevention of Ischemic Stroke, Current Drug Targets 2004; 5 (5) . https://dx.doi.org/10.2174/1389450043345425
DOI https://dx.doi.org/10.2174/1389450043345425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes
Current Diabetes Reviews Emerging Potential of Citrus Flavanones as an Antioxidant in Diabetes and its Complications
Current Topics in Medicinal Chemistry Mitochondria as a Target for Exercise-Induced Cardioprotection
Current Drug Targets A Mini-Review on Cardiovascular and Hematological Complications of COVID-19
Coronaviruses p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Vascular Pharmacology Phenotyping and Genotyping of the Ryanodine Receptor-Associated Genetic Diseases Using Peripheral Lymphocytes
Current Pharmacogenomics Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems
Current Pharmaceutical Design The Role of a Human Hematopoietic Mesenchymal Progenitor in Wound Healing and Fibrotic Diseases and Implications for Therapy
Current Stem Cell Research & Therapy Hypocholesterolemia
Current Vascular Pharmacology Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters